Sensei Biotherapeutics, Inc.
SNSE
$7.96
$0.41395.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.55% | -6.92% | -43.08% | -18.70% | -40.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.14% | -16.68% | -20.61% | 1.11% | -23.48% |
| Operating Income | 33.14% | 16.68% | 20.61% | -1.11% | 23.48% |
| Income Before Tax | 30.89% | 14.11% | -4.80% | -1.81% | 23.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.89% | 14.11% | -4.80% | -1.81% | 23.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.89% | 14.11% | -4.80% | -1.81% | 23.91% |
| EBIT | 33.14% | 16.68% | 20.61% | -1.11% | 23.48% |
| EBITDA | 30.70% | 13.80% | 21.48% | -1.16% | 24.24% |
| EPS Basic | 31.20% | 14.60% | -4.04% | -3.29% | 7.53% |
| Normalized Basic EPS | 31.76% | 12.41% | 17.27% | -3.38% | 5.61% |
| EPS Diluted | 31.20% | 14.60% | -4.04% | -3.29% | 7.53% |
| Normalized Diluted EPS | 31.76% | 12.41% | 17.27% | -3.38% | 5.61% |
| Average Basic Shares Outstanding | 0.46% | 0.57% | 0.73% | -1.43% | -17.72% |
| Average Diluted Shares Outstanding | 0.46% | 0.57% | 0.73% | -1.43% | -17.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |